Recently, RIOK2 dysregulation has been implicated in the progression of various human cancers, including that of non-small cell lung cancer (Liu et al., 2016; Liu et al., 2018), glioblastoma (Read et al., 2013; Song et al., 2020), hepatocellular carcinoma cells (Delman et al., 2019), acute myeloid leukemia (Messling et al., 2021) and prostate cancer8. This evidence concerns the gene RIOK2 and non-small cell lung carcinoma.